BPC-157
A synthetic 15-amino-acid research peptide derived from a protective sequence identified in gastric juice and investigated for cytoprotection, angiogenesis and tissue-repair signalling.
This selector presents the PHONYX research format. It does not initiate a purchase and must not be interpreted as a dose.
Interested in this compound?
Contact the PHONYX team for availability and catalogue information.
What is BPC-157?
BPC-157, also known as Body Protection Compound-157, is a synthetic pentadecapeptide composed of 15 amino acids. Its sequence corresponds to part of a protective protein found in gastric juice. In preclinical research it has been associated with cytoprotective and regenerative activity across gastrointestinal, musculoskeletal, vascular and neural models.
Unlike incretin-based metabolic peptides, BPC-157 belongs to the regenerative-peptide category. Its research profile centres on angiogenesis, nitric-oxide signalling, fibroblast migration, collagen organization and protection of gastric and vascular tissues.
Angiogenesis, cytoprotection and connective-tissue signalling
VEGF / VEGFR2 signalling
Preclinical studies associate BPC-157 with increased VEGF expression and activation of VEGFR2-linked pathways, supporting new-vessel formation in injured tissue models.
Akt–eNOS / nitric oxide
Modulation of the nitric-oxide pathway is linked to vascular and gastrointestinal cytoprotection in animal models.
Fibroblasts and collagen
Research describes increased fibroblast migration, improved cell survival under stress and support for collagen organization during tendon and muscle repair.
Regenerative-peptide research focus
| Compound | Main research pathway | Primary tissue focus | Evidence stage |
|---|---|---|---|
| BPC-157 | VEGFR2 angiogenesis and cytoprotection | Tendons, muscles, ligaments and GI tract | Predominantly preclinical |
| TB-500 | Actin regulation and cell migration | Muscle, cardiac and wound models | Predominantly preclinical |
| GHK-Cu | Collagen, elastin and matrix remodelling | Skin and connective tissue | Preclinical and cosmetic research |
Where BPC-157 has been studied
Musculoskeletal Tendon, ligament and muscle repair
Rat and cell models describe accelerated healing of transected Achilles tendons, dose-dependent migration of tendon fibroblasts, improved cell survival under stress and enhanced repair of injured muscle and ligament tissue.
Gastrointestinal Mucosal cytoprotection
A substantial part of the early evidence concerns gastric and intestinal protection, including ulcer models and NSAID-associated injury. Nitric-oxide signalling is frequently proposed as a central pathway.
Vascular Endothelial and angiogenic research
BPC-157 has been investigated for VEGF/VEGFR2-linked vessel formation, endothelial protection and improved blood supply to slowly healing tissues.
Neural models Experimental nervous-system repair
Animal studies have explored spinal-cord, peripheral-nerve and brain-injury models, but these findings remain experimental and cannot be treated as established human outcomes.
Human evidence Limited and incomplete
Published human data remain limited to small pilot or observational reports. A registered phase II hamstring-strain trial has been reported, but peer-reviewed efficacy results are not yet available.
BPC-157 protocol formats commonly reported in research practice
Conservative protocol
200–300 mcg per day, commonly represented once daily for 2–4 weeks.
Standard protocol
250–500 mcg per day, once daily or divided into two research administrations for 4–6 weeks.
Extended protocol
400–600 mcg per day, once daily or divided, for up to 8 weeks depending on the model.
| Research protocol | Typical amount | Frequency | Typical duration |
|---|---|---|---|
| Conservative | 200–300 mcg/day | Once daily | 2–4 weeks |
| Standard | 250–500 mcg/day | Once daily or split | 4–6 weeks |
| Extended | 400–600 mcg/day | Once daily or split | Up to 8 weeks |
| Acute-injury models | Usually within the conservative-to-standard range | Commonly daily | Shorter observation window |
| Chronic-tissue models | Usually within the standard-to-extended range | Daily or divided | Longer protocol window |
How to interpret the 10 mg vial
Findings reported in experimental models
Angiogenic signalling
Animal studies describe increased VEGF expression and VEGFR2-linked vessel formation in injured tissue.
Tendon-cell migration
In vitro experiments report dose-dependent migration and improved survival of tendon fibroblasts.
Mucosal protection
Ulcer and NSAID-injury models report cytoprotective effects involving nitric-oxide pathways.
Muscle and ligament models
Preclinical studies describe improved organization and healing of injured musculoskeletal tissue.
The available evidence supports continued investigation of BPC-157 in regenerative biology. It does not establish approved treatment, predictable human efficacy or a validated clinical recovery protocol.
Observed tolerability and unresolved risks
Animal toxicology reports have generally described a favourable tolerability profile, but controlled human safety data are sparse. Reported or discussed observations include injection-site redness, headache, transient discomfort, nausea, dizziness and fatigue.
Long-term human safety, immunogenicity, interactions and the implications of stimulated angiogenesis in unwanted contexts remain uncertain. Unverified research materials add separate risks involving identity, purity, sterility, endotoxin content and handling.
A relatively stable gastric-derived sequence with limited human PK data
BPC-157 is described as relatively stable, including in gastric environments, but its systemic persistence is thought to be short. Human pharmacokinetics have not been fully characterized, and most available information comes from animal studies.
PHONYX portfolio format
Evidence behind the key claims
Frequently asked questions
What is BPC-157?
It is a synthetic 15-amino-acid peptide derived from a protective gastric protein sequence and studied in regenerative and cytoprotective models.
What are the main research pathways?
The main pathways discussed in preclinical research are VEGF/VEGFR2 angiogenesis, nitric-oxide signalling, fibroblast migration and collagen organization.
Which tissues have been studied?
Tendons, ligaments, muscles, gastrointestinal mucosa, vascular tissue and selected neural-injury models.
Is BPC-157 clinically approved?
No. It is not an approved medicinal product and human efficacy and safety remain unestablished.
Is there an established human dose?
No. Published experimental dosing is largely from animal models and is usually expressed relative to body weight.
What is the difference between 5 mg and 10 mg formats?
The difference is total lyophilized material in the vial, not purity or composition. The PHONYX portfolio format shown here is 10 mg.
How is lyophilized BPC-157 stored?
Protected from light and moisture, with refrigerated or frozen storage used for longer-term laboratory preservation.
How should a reconstituted laboratory solution be handled?
Store at 2–8°C, avoid repeated freezing, add solvent slowly along the vial wall and avoid vigorous shaking.
Can BPC-157 be studied with other regenerative peptides?
Combined research with TB-500 and GHK-Cu is of interest because the compounds affect different repair-related pathways.
Does research evidence validate a commercial research vial?
No. Published findings apply to the exact material and quality system used in each study, not automatically to unrelated research products.
Research Disclaimer
This compound is presented exclusively for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnostic use, treatment, cure or prevention of disease. Information describing published studies is provided for documentary and educational context only and must not be interpreted as medical advice, a dosing recommendation or instructions for use. BPC-157 is not an approved medicinal product, and its clinical efficacy and safety in humans remain unestablished.